Wissenschaftliche Arbeiten

Prof. Dr. Meral Beksaç

911 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic

    Bone Marrow Transplantation, 2012

    DOI 10.1038/bmt.2011.240 PMID 22139068 12 Zitationen (Europe PMC) Quelle: ORCID

  2. Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A*03, B*44) or Poorer (HLA B*51, C*04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers

    Blood, 2012

    DOI 10.1182/blood.v120.21.4904.4904 Quelle: ORCID

  3. Management of treatment-emergent peripheral neuropathy in multiple myeloma

    Leukemia, 2012

    DOI 10.1038/leu.2011.346 PMID 22193964 193 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  4. Minimal Residual Plasma Cell Content of Autulogous Grafts, Chemosensitivity to Induction or High Dose Therapy and Pre/Post Transplant PET Negativity Predict Long Term Disease Free Survival in Multiple Myeloma

    Blood, 2012

    DOI 10.1182/blood.v120.21.3024.3024 Quelle: ORCID

  5. Myeloma as a second malignancy following AML: Is a second allo equivalent to auto?

    Case Reports in Medicine, 2012

    DOI 10.1155/2012/319530 PMID 22811719 Frei zugänglicher VolltextQuelle: ORCID

  6. PANORAMA 1: A PHASE III STUDY OF PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA

    Haematologica, 2012

    Quelle: ORCID

  7. Predictive value of pre-transplant FDG-PET/CT in newly diagnosed multiple myeloma (MM) patients

    European Journal of Nuclear Medicine and Molecular Imaging, 2012

    Quelle: ORCID

  8. Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study.

    Journal of Clinical Oncology, 2012

    DOI 10.1200/jco.2012.30.15_suppl.8095 14 Zitationen (OpenAlex) Quelle: OpenAlex

  9. Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).

    Journal of Clinical Oncology, 2012

    DOI 10.1200/jco.2012.30.15_suppl.e21006 Quelle: OpenAlex

  10. A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015

    Blood, 2011

    DOI 10.1182/blood.v118.21.475.475 20 Zitationen (OpenAlex) Quelle: ORCID

  11. Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3

    Blood, 2011

    DOI 10.1182/blood-2010-10-299529 PMID 21292778 290 Zitationen (Europe PMC) Quelle: ORCID

  12. Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups

    Blood, 2011

    Quelle: ORCID

  13. High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC

    Blood, 2011

    DOI 10.1182/blood.v118.21.257.257 4 Zitationen (OpenAlex) Quelle: ORCID

  14. LONG-TERM SURVIVORSHIP AFTER ALLOGENEIC HEMATOPOETIC CELL TRANSPLANTATION: STILL ONGOING NON RELAPSE RELATED MORTALITY & MORBIDITY

    Biology of Blood and Marrow Transplantation, 2011

    DOI 10.1016/j.bbmt.2010.12.265 Frei zugänglicher VolltextQuelle: ORCID

  15. Long-term outcome in patients surviving 5 or more years after allogeneic haematopoetic cell transplantation

    Bone Marrow Transplantation, 2011

    Quelle: ORCID

  16. Multiple myeloma treatment strategies with novel agents in 2011: A European perspective

    Oncologist, 2011

    DOI 10.1634/theoncologist.2010-0386 PMID 21441574 21 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  17. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement

    Leukemia, 2011

    DOI 10.1038/leu.2011.3 PMID 21293488 89 Zitationen (Europe PMC) Quelle: ORCID

  18. Peripheral stem cell apheresis in multiple myeloma in the era of new agents

    Bone Marrow Transplantation, 2011

    Quelle: ORCID

  19. Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Blood, 2011

    DOI 10.1182/blood-2011-06-358812 PMID 21841166 254 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  20. Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial

    Leukemia Research, 2011

    DOI 10.1016/j.leukres.2010.07.005 PMID 20673585 12 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  21. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-term follow-up

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2010.32.7312 PMID 21730266 136 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  22. Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials

    Blood, 2011

    DOI 10.1182/blood-2011-03-341669 PMID 21670471 188 Zitationen (Europe PMC) Quelle: ORCID

  23. The role of second allogeneic haematopoietic cell transplantation on relapse of haematological diseases

    Bone Marrow Transplantation, 2011

    Quelle: ORCID

  24. The shaping of modern human immune systems by multiregional admixture with archaic humans

    Science, 2011

    DOI 10.1126/science.1209202 PMID 21868630 333 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  25. First and Second High Dose Treatment Supported by Autologous Hematopoetic Cell Transplantation Rescue in Multiple Myeloma

    Blood, 2011

    DOI 10.1182/blood.v118.21.4528.4528 Quelle: OpenAlex

  26. Immunophenotyping Features in Acute Myeloid Leukemia (AML) with NPM1+ and/or FLT3+

    Blood, 2011

    DOI 10.1182/blood.v118.21.4908.4908 Quelle: OpenAlex

  27. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

    European Journal Of Haematology, 2010

    DOI 10.1111/j.1600-0609.2010.01524.x PMID 20942865 110 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  28. An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells

    Cytotherapy, 2010

    DOI 10.3109/14653249.2010.510506 PMID 20735163 26 Zitationen (Europe PMC) Quelle: OpenAlex

  29. A case of langerhans cell histiocytosis with central diabetes insipidus, hypopituitarism and pulmonary involvement,Santral diabetes i̇nsipidus, hipopituitarizm ve pulmoner tutulum ile giden langerhans hücreli histiyositoz olgusu

    Turkiye Klinikleri Journal of Medical Sciences, 2010

    DOI 10.5336/medsci.2008-8695 Frei zugänglicher VolltextQuelle: ORCID

  30. ALLOGENEIC HEMATOPOETIC CELL TRANSPLANTATION IN PATIENTS POSITIVE FOR HEPATITIS B SURFACE ANTIGEN

    Biology of Blood and Marrow Transplantation, 2010

    DOI 10.1016/j.bbmt.2009.12.395 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  31. Allogeneic haematopoetic cell transplantation in hepatitis B surface antigen positive recipients

    Bone Marrow Transplantation, 2010

    Quelle: ORCID

  32. Allogeneic haematopoietic cell transplantation in paroxysmal nocturnal haemoglobinuria: a therapeutic dilemma from start to discharge

    Bone Marrow Transplantation, 2010

    DOI 10.1038/bmt.2010.45 Frei zugänglicher VolltextQuelle: ORCID

  33. Bronchiolitis obliterans after allogeneic haematopoietic cell transplantation: inpredictable and fatal

    Bone Marrow Transplantation, 2010

    Quelle: ORCID

  34. Comparison of the most frequent haplotypes of Turkish subjects in two registries: TRAN and DKMS

    Tissue Antigens, 2010

    Quelle: ORCID

  35. Comparison of two different chemotherapy regimens for peripheral blood stem cell mobilization in lymphoma

    Bone Marrow Transplantation, 2010

    Quelle: ORCID

  36. Current multiple myeloma treatment strategies with novel agents: A European perspective

    Oncologist, 2010

    DOI 10.1634/theoncologist.2009-0203 PMID 20086168 69 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  37. Donor safety: The role of the WMDA in ensuring the safety of volunteer unrelated donors: Clinical and ethical considerations

    Bone Marrow Transplantation, 2010

    DOI 10.1038/bmt.2010.2 PMID 20173787 39 Zitationen (Europe PMC) Quelle: ORCID

  38. Long-term follow-up of upfront tandem autologous - RIC (reduced intensity conditioning) allogeneic transplantation versus autologous transplantation (NMAM2000) in multiple myeloma

    Bone Marrow Transplantation, 2010

    Quelle: ORCID

  39. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: A randomised trial

    The Lancet Oncology, 2010

    DOI 10.1016/s1470-2045(09)70352-3 PMID 20117965 103 Zitationen (Europe PMC) Quelle: ORCID

  40. MP VERSUS MPT FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A META ANALYSIS OF SURVIVAL OF 1682 INDIVIDUAL PATIENT DATA FROM 6 RANDOMIZED CLINICAL TRIALS

    Haematologica, 2010

    Quelle: ORCID

  41. Multiple Myeloma Patients Who Are Chemosensitive and Present with Plasma Cells Lacking Phosphorylated Retinoblastoma and/or Cyclin A Expression Benefit From High Dose Therapy and Autologous Stem Cell Transplantation More

    Blood, 2010

    DOI 10.1182/blood.v116.21.1345.1345 Quelle: ORCID

  42. PRESENCE OF ABNORMAL PLASMA CELLS IN PERIPHERAL STEM CELL HARVEST PRODUCTS PREDICT EARLY RELAPSE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

    Biology of Blood and Marrow Transplantation, 2010

    DOI 10.1016/j.bbmt.2009.12.257 Frei zugänglicher VolltextQuelle: ORCID

  43. RANDOMIZED PHASE 2 TRIAL OF BORTEZOMIB-DEXAMETHASONE (VD) VERSUS VD PLUS CYCLOPHOSPHAMIDE OR LENALIDOMIDE IN MYELOMA PATIENTS ACHIEVING STABLE DISEASE AFTER 4 CYCLES OF VD AS SECOND-LINE TREATMENT

    Haematologica, 2010

    Quelle: ORCID

  44. Use of High-Dose Chemotherapy plus Granulocyte Colony-Stimulating Factor for the Salvage of Refractory or Resistant-Relapse Lymphoma Patients without Stem Cell Support

    Acta Haematologica, 2009

    DOI 10.1159/000203607 PMID 9352743 Quelle: OpenAlex

  45. 5-azacytidine treatment results in myelodysplastic syndrome

    Journal of Clinical Oncology, 2009

    DOI 10.1200/jco.2009.27.15_suppl.e18003 Quelle: ORCID

  46. Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial From the Turkish Myeloma Study Group

    Blood, 2009

    Quelle: ORCID

  47. Autologous stem cell transplantation (ASCT) versus ASCT followed by reduced-intensity conditioning (RIC) allogeneic SCT with identical sibling donor in previously untreated multiple myeloma (MM): a prospective controlled trial by the EBMT

    Bone Marrow Transplantation, 2009

    Quelle: ORCID

  48. HLA specificities/haplotypes of patients who have no matched donors available worldwide: a report from TRAN-Turkey

    Tissue Antigens, 2009

    Quelle: ORCID

  49. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

    Leukemia, 2009

    DOI 10.1038/leu.2009.89 PMID 19421229 299 Zitationen (Europe PMC) Quelle: ORCID

  50. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: A randomized evaluation of early vs late administration of recombinant human G-CSF

    Bone Marrow Transplantation, 2009

    DOI 10.1038/bmt.2009.161 PMID 19597420 12 Zitationen (Europe PMC) Quelle: ORCID